Home Cart Sign in  
Chemical Structure| 1397219-81-6 Chemical Structure| 1397219-81-6

Structure of BS-181 HCl
CAS No.: 1397219-81-6

Chemical Structure| 1397219-81-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

BS-181 is a selective CDK7 inhibitor with IC50 of 21 nM.

Synonyms: BS-181 (hydrochloride); BS-181 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of BS-181 HCl

CAS No. :1397219-81-6
Formula : C22H33ClN6
M.W : 416.99
SMILES Code : CC(C1=C2N=C(NCCCCCCN)C=C(NCC3=CC=CC=C3)N2N=C1)C.[H]Cl
Synonyms :
BS-181 (hydrochloride); BS-181 hydrochloride
MDL No. :MFCD18384975
InChI Key :NVIJWMOQODWNFN-UHFFFAOYSA-N
Pubchem ID :49867928

Safety of BS-181 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of BS-181 HCl

Hedgehog

Isoform Comparison

Biological Activity

Target
  • CDK7

    CDK7, IC50:21 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
BGC823 0 μM, 1 μM, 10 μM, 20 μM 12 hours, 24 hours, 48 hours, 72 hours BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP, inducing cell cycle arrest and apoptosis. PMC4801149
Jurkat A3 5, 10, 15, 20 μM 20 h BS-181 caused cytotoxicity and several apoptotic events, including TRAIL/DR4/DR5 upregulation, c-FLIP down-regulation, BID cleavage, BAK activation, ΔΨm loss, caspase-8/9/3 activation, and PARP cleavage. PMC7766600
Jurkat JT/Neo 10, 15 μM 24 h BS-181 induced BAK activation and ΔΨm loss, with significant increases in BAK activation rates and ΔΨm loss in JT/Neo cells. PMC7766600
Jurkat JT/BCL-2 10, 15 μM 24 h BS-181-induced BAK activation and ΔΨm loss were abrogated in JT/BCL-2 cells. PMC7766600
MCF-7 25 μM 24 hours BS-181 treatment led to an increase in G1 phase cells and induced apoptosis. PMC2875168
MCF-7 50 μM 24 hours BS-181 treatment led to an increase in G1 phase cells and induced apoptosis. PMC2875168
MH7A cells 80 nM 24 hours BS-181 significantly down-regulated the mRNA levels of IL-1β, IL-6, IL-8 and RANKL, suggesting inhibition of CDK7 by BS-181 effectively suppressed LPS-induced MH7A inflammation. PMC5783872
FLS cells 80 nM 24 hours BS-181 significantly down-regulated transcript levels of IL-1β, IL-6, IL-8 and RANKL in LPS-induced FLS cells, suggesting BS-181 effectively suppressed LPS-induced FLS cell inflammation. PMC5783872
HeLa cells 1 μM, 3 μM, 5 μM, 10 μM, 20 μM 30 minutes To test the effect of CDK7 inhibitors on in vitro transcription, results showed that compound 140 significantly inhibited transcription at low concentrations PMC4187722
A549 cells 0.05 μM, 0.1 μM, 0.3 μM, 0.5 μM, 1 μM 30 minutes To test the effect of CDK7 inhibitors on in vitro transcription, results showed that compound 297 significantly inhibited transcription at low concentrations PMC4187722

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c-nu mice Human gastric cancer xenograft model Intraperitoneal injection 10 mg/kg/d, 20 mg/kg/d Twice daily for 14 days BS-181 significantly inhibited tumor growth and increased survival rate. PMC4801149
Nude mice MCF-7 human xenograft model Intraperitoneal injection 10 mg/kg/day and 20 mg/kg/day Twice daily for 14 days BS-181 significantly inhibited the growth of MCF-7 tumors with no apparent toxicity. PMC2875168

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

11.99mL

2.40mL

1.20mL

23.98mL

4.80mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories